4.6 Review

Next-generation anti-VEGF agents for diabetic macular oedema

Journal

EYE
Volume 36, Issue 2, Pages 273-277

Publisher

SPRINGERNATURE
DOI: 10.1038/s41433-021-01722-8

Keywords

-

Categories

Ask authors/readers for more resources

Intravitreal injections have improved the treatment of diabetic macular oedema (DMO), but real-world data shows a disparity between clinical trials and daily practice. Long-lasting drugs and devices may bridge this gap, offering more feasible treatment options to control the global epidemic of diabetic eye disease.
The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available